Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
In a collaborative breakthrough that may redefine the clinical understanding of psychiatric disorders, researchers from the University of Queensland and…
Read More
A team of biomedical researchers at Michigan State University (MSU) has announced the identification of a critical molecular "switch" that…
Read More